RxDoctor Payments Data

David Schwartz

Pulmonary Disease · Aurora, CONPI 1790869675

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $470,933 of the $471,100 with a category attached, or 100.0%. Vertex accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $137,500 and has fallen 100.0% since, to $22 in 2023. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$471,100in general payments, 2019–2025

Across 55 payments — averaging $8565.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$471K
  • AstraZeneca$22
$6,251,573in research payments, 2019–2025

Across 5 payments — averaging $1,250,315 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$6.3M

What the payments were for

  • Consulting fees$470,933100%
  • Food & beverage$1670%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex54$471,078
AstraZeneca1$22

How this compares

$471,100 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado →

Other pulmonary disease in Aurora

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →